Anneke Kastelein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anneke Kastelein has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jacques Neefjes
Department of Cell and Chemical Biology, ONCODE Institute, Leiden University Medical Center
3 shared publications - Hans Gelderblom
Leiden University Medical Center Leiden Netherlands
2 shared publications - Laura Kervezee
Department of Cell and Chemical Biology, Leiden University Medical Center, Netherlands
2 shared publications Amy Chin On
1 shared publicationAnke M. Smits
1 shared publication- Anne M. May
Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 139
Doxorubicin administration modulates cancer-related fatigue in a time-of-day-dependent manner
- 20 August 2026
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 139
Open AccessDoxorubicin administration modulates cancer-related fatigue in a time-of-day-dependent manner
- Open Access
- 14 January 2026
- Published by Elsevier in The Breast
- Vol. 85, 104700
The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy
- 14 January 2026
- Published by Elsevier in The Breast
- Vol. 85, 104700
Open AccessThe trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy
- Open Access
- 6 January 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (1) , e70536
The Impact of Chemotherapy and Body Mass Index on Cancer‐Related Fatigue in Colon Cancer Patients: A PROFILES ‐Registry Study
Background: Inflammation has been reported to drive cancer‐related fatigue (CRF). As both obesity and chemotherapy promote inflammatory responses, obese cancer patients may be at risk of more severe CRF, especially when receiving chemotherapy. Methods: We analysed data of 333 colon cancer patients from four hospitals in the Netherlands (data derived from the PROCORE study). Fatigue was assessed with the general fatigue subscale of the Multidimensional Fatigue Inventory at four timepoints: at inclusion (T1), 4 weeks after surgery (T2), and 1 (T3) and 2 years (T4) after diagnosis. Linear mixed‐effects models were applied to evaluate the interaction between chemotherapy and body mass index (BMI) on the trajectory of fatigue. Results: The two‐way interactions between time and chemotherapy ( p = 0.047) and between time and BMI on fatigue ( p = 0.041) were significant. Patients scheduled for chemotherapy reported more fatigue during the treatment phase, while patients not treated with chemotherapy showed a stable trajectory. Obese patients reported more fatigue at follow‐up compared to patients with a healthy BMI. The three‐way interaction between time, chemotherapy and BMI was not significant ( p = 0.39). However, obese chemotherapy‐treated patients reported the highest fatigue 2 years after treatment (12.8, 95% CI: 10.6–14.9). Their mean fatigue score was higher compared to baseline (9.2, 95% CI: 7.3–11.0, p < 0.001) and obese patients not treated with chemotherapy (9.6, 95% CI: 7.0–12.2, p = 0.02). Moreover, this group reported more fatigue compared to healthy (8.1, 95% CI: 5.5–10.9, p < 0.001) and overweight (9.7, 95% CI: 7.2–12.3, p = 0.019) chemotherapy‐treated patients. Conclusion: This study indicates that chemotherapy and BMI both influence long‐term fatigue in colon cancer patients. Proactive monitoring for CRF and lifestyle interventions may be needed for chemotherapy‐treated patients with a high BMI.
- 6 January 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (1) , e70536
Open AccessThe Impact of Chemotherapy and Body Mass Index on Cancer‐Related Fatigue in Colon Cancer Patients: A PROFILES ‐Registry Study
Background: Inflammation has been reported to drive cancer‐related fatigue (CRF). As both obesity and chemotherapy promote inflammatory responses, obese cancer patients may be at risk of more severe CRF, especially when receiving chemotherapy. Methods: We analysed data of 333 colon cancer patients from four hospitals in the Netherlands (data derived from the PROCORE study). Fatigue was assessed with the general fatigue subscale of the Multidimensional Fatigue Inventory at four timepoints: at inclusion (T1), 4 weeks after surgery (T2), and 1 (T3) and 2 years (T4) after diagnosis. Linear mixed‐effects models were applied to evaluate the interaction between chemotherapy and body mass index (BMI) on the trajectory of fatigue. Results: The two‐way interactions between time and chemotherapy ( p = 0.047) and between time and BMI on fatigue ( p = 0.041) were significant. Patients scheduled for chemotherapy reported more fatigue during the treatment phase, while patients not treated with chemotherapy showed a stable trajectory. Obese patients reported more fatigue at follow‐up compared to patients with a healthy BMI. The three‐way interaction between time, chemotherapy and BMI was not significant ( p = 0.39). However, obese chemotherapy‐treated patients reported the highest fatigue 2 years after treatment (12.8, 95% CI: 10.6–14.9). Their mean fatigue score was higher compared to baseline (9.2, 95% CI: 7.3–11.0, p < 0.001) and obese patients not treated with chemotherapy (9.6, 95% CI: 7.0–12.2, p = 0.02). Moreover, this group reported more fatigue compared to healthy (8.1, 95% CI: 5.5–10.9, p < 0.001) and overweight (9.7, 95% CI: 7.2–12.3, p = 0.019) chemotherapy‐treated patients. Conclusion: This study indicates that chemotherapy and BMI both influence long‐term fatigue in colon cancer patients. Proactive monitoring for CRF and lifestyle interventions may be needed for chemotherapy‐treated patients with a high BMI.
- Open Access
Induction of Fatigue by Specific Anthracycline Cancer Drugs through Disruption of the Circadian Pacemaker
Cancer-related fatigue (CRF) is the most devastating long-term side effect of many cancer survivors that confounds the quality of life for months to years after treatment. However, the cause of CRF is poorly understood. As a result, cancer survivors, at best, receive psychological support. Chemotherapy has been shown to increase the risk of CRF. Here, we study therapy-induced fatigue in a non-tumor-bearing mouse model with three different topoisomerase II-poisoning cancer drugs. These drugs either induce DNA damage and/or chromatin damage. Shortly before and several weeks after treatment, running wheel activity and electroencephalographic sleep were recorded. We show that doxorubicin, combining DNA damage with chromatin damage, unlike aclarubicin or etoposide, induces sustained CRF in this model. Surprisingly, this was not related to changes in sleep. In contrast, our data indicate that the therapy-induced CRF is associated with a disrupted circadian clock. The data suggest that CRF is probably a circadian clock disorder that influences the quality of waking and that the development of CRF depends on the type of chemotherapy provided. These findings could have implications for selecting and improving chemotherapy for the treatment of cancer in order to prevent the development of CRF.
Open AccessInduction of Fatigue by Specific Anthracycline Cancer Drugs through Disruption of the Circadian Pacemaker
Cancer-related fatigue (CRF) is the most devastating long-term side effect of many cancer survivors that confounds the quality of life for months to years after treatment. However, the cause of CRF is poorly understood. As a result, cancer survivors, at best, receive psychological support. Chemotherapy has been shown to increase the risk of CRF. Here, we study therapy-induced fatigue in a non-tumor-bearing mouse model with three different topoisomerase II-poisoning cancer drugs. These drugs either induce DNA damage and/or chromatin damage. Shortly before and several weeks after treatment, running wheel activity and electroencephalographic sleep were recorded. We show that doxorubicin, combining DNA damage with chromatin damage, unlike aclarubicin or etoposide, induces sustained CRF in this model. Surprisingly, this was not related to changes in sleep. In contrast, our data indicate that the therapy-induced CRF is associated with a disrupted circadian clock. The data suggest that CRF is probably a circadian clock disorder that influences the quality of waking and that the development of CRF depends on the type of chemotherapy provided. These findings could have implications for selecting and improving chemotherapy for the treatment of cancer in order to prevent the development of CRF.